As a follow-on from our previous study demonstrating that FGFR2 activates RSK2 in BCa cells in vitro [19], herein we have undertaken an evaluation of a potential clinical significance of an interaction between FGFR2 and RSK2 in breast cancer. Here, RPS6KA3 is linked to breast cancer.